-+ 0.00%
-+ 0.00%
-+ 0.00%

Jefferies Maintains Buy on Ascendis Pharma, Lowers Price Target to $330

Benzinga·08/31/2026 17:31:03
Listen to the news
Jefferies analyst Kelly Shi maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $333 to $330.